BriaCell Therapeutics Corp. (BCTXZ)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Peers in industry
BriaCell Therapeutics Corp. has no peer companies in this window.
Recent press releases
BriaCell Therapeutics Corp. has not issued a press release in this window.
SEC filings
All filings →BriaCell Therapeutics Corp. has not filed an SEC document in this window.
Insider trades
All insider trades →BriaCell Therapeutics Corp. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at BriaCell Therapeutics Corp.
All people →No officers or directors have been indexed for BriaCell Therapeutics Corp..